CClinicalTrials.gg
Sign In
CompletedNCT00296374PLANET 1Updated Sep 1, 2011Results posted

Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

A Phase 2 interventional study of Rosuvastatin and Rosuvastatin in Diabetes Mellitus, sponsored by AstraZeneca. Completed at 116 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-09-01.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
353
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in patients with Type 1 or 2 diabetes with moderate proteinuria and hypercholesterolaemia.

02

Conditions studied

  • Diabetes Mellitus

Keywords

  • Hyperlipidemia
  • Proteinuria
  • Diabetes Mellitus
03

In context

Proteinuria

234 studies on the registry are indexed under Proteinuria; 43 are open to participants now.

This study's enrollment of 353 is above the median of 60 across 164 interventional studies indexed under Proteinuria.

Browse Proteinuria studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.

Of its 358 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.

Browse AstraZeneca studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • hyperlipidemia
  • urinary protein
  • diabetes

Exclusion criteria

Exclusion Criteria:

  • previous rosuvastatin treatment \< 6 months prior to Visit 1
  • statin intolerance
  • severe hypertension
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
353 participants (actual)

Study arms

  • Experimental
    1

    Rosuvastatin 10 mg

    Drug: Rosuvastatin

  • Experimental
    2

    Rosuvastatin 40 mg

    Drug: Rosuvastatin

  • Active comparator
    3

    Atorvastatin 80 mg

    Drug: Atorvastatin

Interventions

  • DrugRosuvastatin

    10 mg oral dose administered once daily for 52 weeks

    Also known as: Crestor

  • DrugRosuvastatin

    20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks

    Also known as: Crestor

  • DrugAtorvastatin

    40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks

    Also known as: Lipitor

06

What researchers measure

Primary outcomes

  1. Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes.

    Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.

    Time frame: Assessed at Week 52, Last observation carried forward (LOCF)

Secondary outcomes

  1. Urinary Protein/Creatinine Ratio at Week 26.

    Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio.

    Time frame: Assessed at Week 26

  2. Urinary Albumin/Creatinine Ratio at Week 26

    Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.

    Time frame: Assessed at Week 26

  3. Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]

    Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.

    Time frame: Assessed at Week 52 LOCF

  4. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26

    Time frame: Assessed at Baseline and Week 26

  5. Change From Baseline in eGFR at Week 52 [LOCF]

    Time frame: Assessed at Baseline and Week 52 [LOCF]

  6. Correlation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52 (LOCF).

    Time frame: 52 weeks

  7. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: Assessed at 52 Weeks

  8. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C]

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  9. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  10. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C]

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  11. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  12. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C]

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  13. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  14. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG]

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  15. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  16. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  17. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  18. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  19. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  20. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  21. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  22. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1]

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  23. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-1

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  24. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB]

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  25. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  26. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  27. Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio

    Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  28. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  29. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  30. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  31. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  32. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  33. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  34. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  35. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  36. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  37. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  38. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  39. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  40. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  41. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  42. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  43. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  44. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  45. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  46. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  47. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  48. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  49. Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio

    Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  50. Relationship Between Renal Effects and Lipid Changes: eGFR and TC

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  51. Relationship Between Renal Effects and Lipid Changes: eGFR and TC

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  52. Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  53. Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  54. Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  55. Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 Weeks

  56. Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  57. Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 weeks

  58. Relationship Between Renal Effects and Lipid Changes: eGFR and TG

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  59. Relationship Between Renal Effects and Lipid Changes: eGFR and TG

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 weeks

  60. Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  61. Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 weeks

  62. Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  63. Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 weeks

  64. Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  65. Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 weeks

  66. Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  67. Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 weeks

  68. Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  69. Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 weeks

  70. Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

    Time frame: 26 weeks

  71. Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio

    Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

    Time frame: 52 weeks

07

Results

Posted Dec 30, 2010

Participant flow

353 patients entered the study with Type 1 or 2 diabetes and were receiving current treatment with angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs). The study was conducted at 147 centers in 11 countries.

Participant flow — Overall Study
MilestoneRosuvastatin 10mgRosuvastatin 40mgAtorvastatin 80mg
Started118124111
Completed9310182
Not completed252329
Withdrew: Adverse event14107
Withdrew: Withdrawal by subject3511
Withdrew: Incorrect enrollment334
Withdrew: Protocol violation123
Withdrew: Lost to follow-up311
Withdrew: Relocated to another state100
Withdrew: Stopped drug before end of study visit010
Withdrew: Nephrologist introduced ace010
Withdrew: Pregnancy002
Withdrew: Other001

Outcome measures

PrimaryUrinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes.

Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.

Time frame:
Assessed at Week 52, Last observation carried forward (LOCF)
Reported as:
Geometric mean · mg/g
Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes.
mg/gRosuvastatin 10mgRosuvastatin 40mgAtorvastatin 80mg
Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes.1.016 (0.858 to 1.209)0.955 (0.869 to 1.185)0.874 (0.733 to 0.975)
SecondaryUrinary Protein/Creatinine Ratio at Week 26.

Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio.

Time frame:
Assessed at Week 26
Reported as:
Geometric mean · mg/g
Urinary Protein/Creatinine Ratio at Week 26.
mg/gRosuvastatin 10mgRosuvastatin 40mgAtorvastatin 80mg
Urinary Protein/Creatinine Ratio at Week 26.1.007 (0.895 to 1.133)0.994 (0.881 to 1.121)0.876 (0.784 to 0.979)
SecondaryUrinary Albumin/Creatinine Ratio at Week 26

Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.

Time frame:
Assessed at Week 26
Reported as:
Geometric mean · mg/g
Urinary Albumin/Creatinine Ratio at Week 26
mg/gRosuvastatin 10mgRosuvastatin 40mgAtorvastatin 80mg
Urinary Albumin/Creatinine Ratio at Week 260.927 (0.792 to 1.085)0.913 (0.788 to 1.058)0.831 (0.726 to 0.951)
SecondaryUrinary Albumin/Creatinine Ratio at Week 52 [LOCF]

Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.

Time frame:
Assessed at Week 52 LOCF
Reported as:
Geometric mean · mg/g
Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]
mg/gRosuvastatin 10mgRosuvastatin 40mgAtorvastatin 80mg
Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]1.016 (0.856 to 1.206)0.836 (0.704 to 0.993)0.823 (0.709 to 0.954)
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26
Time frame:
Assessed at Baseline and Week 26
Reported as:
Mean · mL/min
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26
mL/minRosuvastatin 10mgRosuvastatin 40mgAtorvastatin 80mg
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26-2.73 ± 12.644-5.46 ± 14.079-1.78 ± 10.997
SecondaryChange From Baseline in eGFR at Week 52 [LOCF]
Time frame:
Assessed at Baseline and Week 52 [LOCF]
Reported as:
Mean · mL/min
Change From Baseline in eGFR at Week 52 [LOCF]
mL/minRosuvastatin 10 mgRosuvastatin 40 mgAtorvastatin 80 mg
Change From Baseline in eGFR at Week 52 [LOCF]-3.70 ± 14.551-7.29 ± 20.040-1.61 ± 12.769
SecondaryCorrelation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52 (LOCF).

Time frame:
52 weeks
Reported as:
Number · Correlation coefficient
Correlation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Correlation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes-0.035070.142580.01600
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
Assessed at 52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC0.070190.268550.12013
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C]

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C]
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C]-0.085880.18570-0.02491
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C0.045100.162800.06739
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C]

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C]
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C]0.156140.069870.14226
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C0.161110.261940.18918
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C]

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C]
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C]-0.120680.15929-0.05186
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C0.025940.240180.07381
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG]

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG]
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG]-0.145690.04948-0.08471
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG-0.052510.117550.01345
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio-0.135720.07339-0.08855
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio-0.059450.12132-0.02666
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio-0.136890.12931-0.08108
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio-0.027750.06535-0.01569
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio-0.167550.08891-0.11221
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio-0.060850.12507-0.02841
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1]

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1]
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1]0.158590.131330.15516
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-1

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-1
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-10.165870.184690.18832
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB]

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB]
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB]-0.022760.214050.04578
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB0.053970.294860.11079
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio-0.078460.13910-0.02825
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio

Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio0.006000.227100.03684
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC0.006420.143310.04311
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC0.132200.357150.18971
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C-0.055140.198420.00038
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C0.100370.212050.12270
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C0.085930.000320.06930
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C0.147580.268050.17550
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C-0.066940.17296-0.01144
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C0.091890.337690.14988
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG-0.072710.08654-0.02876
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG-0.029470.271980.08787
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio-0.047850.11256-0.01362
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio0.017980.201270.05369
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio-0.082110.16654-0.03001
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio0.034760.109020.04508
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio-0.084680.12805-0.04102
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio0.015280.211980.05251
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-10.142070.111710.13429
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-10.160850.159330.17306
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB-0.005690.200080.04833
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB0.109970.305370.15652
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio-0.059060.13706-0.01775
SecondaryRelationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio

Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio0.047600.256360.07766
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and TC

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and TC
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and TC0.01586-0.031240.00101
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and TC

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and TC
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and TC-0.13489-0.18105-0.14690
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and LDL-C

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C0.03010-0.009440.02609
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and LDL-C

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C-0.11072-0.12835-0.11378
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and HDL-C

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C0.113730.011230.07576
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and HDL-C

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 Weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C0.14457-0.155460.08841
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C-0.01709-0.05610-0.02569
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C-0.17729-0.19501-0.17911
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and TG

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and TG
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and TG-0.10533-0.00604-0.09437
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and TG

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and TG
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and TG-0.24494-0.07059-0.15586
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio-0.05426-0.01643-0.04256
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio-0.26268-0.08593-0.23226
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio-0.010400.002410.00189
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio-0.19850-0.06481-0.17579
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio-0.06356-0.04402-0.05499
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio-0.26802-0.11804-0.24204
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and ApoA1

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA10.081460.053330.05845
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and ApoA1

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA10.179090.080900.12787
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and ApoB

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB-0.014270.088210.00737
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and ApoB

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB-0.151460.04886-0.12168
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26.

Time frame:
26 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio-0.040880.06598-0.01652
SecondaryRelationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio

Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52

Time frame:
52 weeks
Reported as:
Number · Correlation coefficient
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio
Correlation coefficientRosuvastatinAtorvastatinAll Treatment
Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio-0.261460.05248-0.22109

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin 10mg—18/116 (15.5%)15/116 (12.9%)
Rosuvastatin 40mg—20/123 (16.3%)25/123 (20.3%)
Atorvastatin 80mg—21/110 (19.1%)12/110 (10.9%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventRosuvastatin 10mgRosuvastatin 40mgAtorvastatin 80mg
Cardiac FailureCardiac disorders3/1161/1231/110
Angina PectorisCardiac disorders2/1161/1232/110
Diabetes Mellitus Inadequate ControlMetabolism and nutrition disorders0/1160/1232/110
Abortion SpontaneousPregnancy, puerperium and perinatal conditions0/1160/1232/110
Oedema PeripheralGeneral disorders2/1160/1230/110
Renal Failure AcuteRenal and urinary disorders0/1162/1230/110
Acute Myocardial InfarctionCardiac disorders1/1160/1231/110
Angina UnstableCardiac disorders0/1160/1231/110
Atrial FibrillationCardiac disorders0/1160/1231/110
Myocardial IschaemiaCardiac disorders0/1160/1231/110
Most frequent other events
Most frequent other events
EventRosuvastatin 10mgRosuvastatin 40mgAtorvastatin 80mg
Oedema PeripheralGeneral disorders9/1165/1233/110
HypertensionVascular disorders2/1168/1232/110
MyalgiaMusculoskeletal and connective tissue disorders3/1166/1237/110
InfluenzaInfections and infestations3/1167/1230/110

Baseline characteristics

Age, Customized
Age, Customized(Participants)Rosuvastatin 10mgRosuvastatin 40mgAtorvastatin 80mgTotal
18-49 years22332580
50-64 years595957175
>=65 years37322998
Sex: Female, Male
Sex: Female, Male(Participants)Rosuvastatin 10mgRosuvastatin 40mgAtorvastatin 80mgTotal
Female433233108
Male759278245
Estimated glomerular filtration rate [eGFR]
Estimated glomerular filtration rate [eGFR](mL/min)Rosuvastatin 10mgRosuvastatin 40mgAtorvastatin 80mgTotal
Mean68.759 ± 24.108072.644 ± 25.801872.149 ± 24.872171.210 ± 24.9455
Urine albumin/creatinine ratio
Urine albumin/creatinine ratio(mg/g)Rosuvastatin 10mgRosuvastatin 40mgAtorvastatin 80mgTotal
Mean1036.478 ± 730.61851079.802 ± 725.70391143.198 ± 779.52821085.435 ± 743.5360
Urine protein/creatinine ratio
Urine protein/creatinine ratio(mg/g)Rosuvastatin 10mgRosuvastatin 40mgAtorvastatin 80mgTotal
Mean1392.26 ± 888.32151493.574 ± 996.09721517.858 ± 969.70201467.843 ± 952.0380
08

Study locations

116 sites
  • Research Site
    Avondale, Arizona, United States
  • Research Site
    Phoenix, Arizona, United States
  • Research Site
    Jonesboro, Arkansas, United States
  • Research Site
    Pasadena, California, United States
  • Research Site
    Riverside, California, United States
  • Research Site
    Santa Ana, California, United States
  • Research Site
    West Hills, California, United States
  • Research Site
    Hollywood, Florida, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    West Palm Beach, Florida, United States
  • Research Site
    Augusta, Georgia, United States
  • Research Site
    Topeka, Kansas, United States
  • Research Site
    Springfield, Massachusetts, United States
  • Research Site
    Detroit, Michigan, United States
  • Research Site
    Columbia, Missouri, United States
  • Research Site
    St. Louis, Missouri, United States
  • Research Site
    Orchard Park, New York, United States
  • Research Site
    Stony Brook, New York, United States
  • Research Site
    Winston Salem, North Carolina, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Kettering, Ohio, United States
  • Research Site
    Pittsburg, Pennsylvania, United States
  • Research Site
    Columbia, South Carolina, United States
  • Research Site
    Dallas, Texas, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    Lubbock, Texas, United States
  • Research Site
    San Antonio, Texas, United States
  • Research Site
    Ogden, Utah, United States
  • Research Site
    Milwaukee, Wisconsin, United States
  • Research Site
    Buenos Aires, Argentina
  • Reasearch Site
    La Plata, Argentina
  • Research Site
    Moron, Argentina
  • Research Site
    Quilmes, Argentina
  • Research Site
    Curitiba, Brazil
  • Research Site
    Fortaleza, Brazil
  • Research Site
    Goiania, Brazil
  • Research Site
    Recife, Brazil
  • Research Site
    Sao Paulo, Brazil
  • Research Site
    Burgas, Bulgaria
  • Research Site
    Gabrovo, Bulgaria
  • Research Site
    Pleven, Bulgaria
  • Research Site
    Plovdiv, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Varna, Bulgaria
  • Research Site
    Veliko Tarnovo, Bulgaria
  • Research Site
    Vancouver, British Columbia, Canada
  • Research Site
    Courtice, Ontario, Canada
  • Research Site
    North York, Ontario, Canada
  • Research Site
    Oshawa, Ontario, Canada
  • Research Site
    Ottawa, Ontario, Canada
  • Research Site
    Richmond Hill, Ontario, Canada
  • Research Site
    Scarborough, Ontario, Canada
  • Research Site
    Thunder Bay, Ontario, Canada
  • Research Site
    Greenfield Park, Quebec, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Aalborg, Denmark
  • Research Site
    Blegdamsvej 9, Denmark
  • Research Site
    Farso, Denmark
  • Research Site
    Gentofte, Denmark
  • Research Site
    Hillerod, Denmark
  • Research Site
    Hvidovre, Denmark
  • Research Site
    Koge, Denmark
  • Research Site
    Annonay, France
  • Research Site
    Besançon, France
  • Research Site
    Bondy, France
  • Research Site
    Colmar, France
  • Research Site
    Corbeil Essonnes, France
  • Research Site
    Corsept, France
  • Research Site
    Creil Cedex, France
  • Research Site
    Grenoble Cedex, France
  • Research Site
    La Chapelle Sur Erdre, France
  • Research Site
    Nantes, France
  • Research Site
    Paris, France
  • Research Site
    Pessac, France
  • Research Site
    Quimper, France
  • Research Site
    Baja, Hungary
  • Research Site
    Balatonfured, Hungary
  • Research site
    Budapest, Hungary
  • Research Site
    Debrecen, Hungary
  • Research Site
    Gyor, Hungary
  • Research site
    Gyula, Hungary
  • Research Site
    Hodmeztvasarhely, Hungary
  • Research Site
    Kecskemét, Hungary
  • Research Site
    Keszthely, Hungary
  • Research Site
    Miskolc, Hungary
  • Research Site
    Mosonmagyarovar, Hungary
  • Research Site
    Nyiregyhaza, Hungary
  • Research Site
    Szolnok, Hungary
  • Research Site
    Székesfehérvár, Hungary
  • Research Site
    Tatabanya, Hungary
  • Research Site
    Zalaegerszeg, Hungary
  • Research Site
    Acireale, CT, Italy
  • Research Site
    Firenze, FI, Italy
  • Research Site
    Roma, RM, Italy
  • Research Site
    Sottomarnia Di Chioggia, VE, Italy
  • Research Site
    Bergamo, Italy
  • Research Site
    Cagliari, Italy
  • Research Site
    Milano, Italy
  • Research Site
    San Giovanni Rotondo, Italy
  • Research Site
    Sassari, Italy

Showing the first 100 of 116 sites across 11 countries.

09

References and documents

Publications

  • de Zeeuw D, Anzalone DA, Cain VA, Cressman MD, Heerspink HJ, Molitoris BA, Monyak JT, Parving HH, Remuzzi G, Sowers JR, Vidt DG. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015 Mar;3(3):181-90. doi: 10.1016/S2213-8587(14)70246-3. Epub 2015 Feb 4. PubMed 25660356 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00296374
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 27, 2006
Start date
Feb 2006
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Dec 30, 2010
Last update
Sep 1, 2011

Study contacts

AstraZeneca Crestor Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Proteinuria→

Other studies from this sponsor

AstraZeneca→

Start the discussion